22066 Federal Register / Vol. 61, No. 93 / Monday, May 13, 1996 / Notices

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

SUMMARY: The invention referenced

below is owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

U.S. Patent 4,790,987 issued on

December 13, 1988 and entitled ‘‘Viral

Glycoprotein Subunit Vaccine’’—This

patent discloses subunit vaccine

compositions for the prevention of viral

infections including influenza virus,

parainfluenza virus, herpes virus,

paramyxoviruses, rabies virus, and

human T-cell lymphotrophic viruses.

The patent also discloses a method for

preparing the vaccine compositions. A

novel feature of the invention is the

utilization of a dialyzable detergent for

solubilization of the active component,

which allows a relatively simple

purification process on a large scale.

Thus, these vaccines are easier to

prepare than other glycoprotein subunit

vaccines and retain their antigenicity to

a greater extent than formalininactivated subunit vaccines.

The invention claimed in this patent

is available for licensing on a

nonexclusive basis. Interested parties

should respond by June 12, 1996.

ADDRESSES: Licensing information and a

copy of the issued patent may be

obtained by contacting Cindy K. Fuchs,

J.D., at the Office of Technology

Transfer, National Institutes of Health,

6011 Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804

(telephone 301/496–7735 ext 232; fax

301/402–0220).

Dated: May 1, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 96–11907 Filed 5–10–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

SUMMARY: The invention referenced

below is owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

U.S. Patent 4,788,181 issued on

November 29, 1988 and entitled ‘‘5-

Substituted-2′,3′-Dideoxycytidine

Compounds with Anti-HTLV–III

Activity’’—5-substituted-2′,3′-

dideoxycytidine analogs and their

phosphorylated derivatives are effective

inhibitors of HTLV–III/LAV (HIV)

infection, especially in the brain.

Although the parent compound 2′,3′-

dideoxycytidine can scarcely enter the

central nervous system, 2′,3′-dideoxy-5-

fluorocytidine readily penetrates the

blood-brain barrier and, thus, is more

effective against the AIDS virus in the

brain.

The invention claimed in this patent

is available for licensing on either an

exclusive or nonexclusive basis.

Interested parties should respond by

August 12, 1996.

ADDRESSES: Licensing information and a

copy of the issued patent may be

obtained by contacting Robert Benson at

the Office of Technology Transfer,

National Institutes of Health, 6011

Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804

(telephone 301/496–7056 ext 267; fax

301/402–0220).

Dated: May 2, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 96–11909 Filed 5–10–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Mental Health;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Institute of Mental

Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: May 17, 1996.

Time: 10 a.m.

Place: Parklawn, Room 9C–18, 5600

Fishers Lane, Rockville, MD 20857.

For Further Information Contact: Angela L.

Redlingshafer, Parklawn, Room 9C–18, 5600

Fishers Lane, Rockville, MD 20857,

Telephone: 301, 443–1367.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than

fifteen days prior to the meeting due to the

urgent need to meet timing limitations

imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Numbers 93.242, 93.281, 93.282)

Dated: May 7, 1996.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 96–11906 Filed 5–10–96; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

National Toxicology Program;

Announcement of Intent To Conduct

Toxicological Studies of 9 Chemicals

Request for Comments: As part of an

effort to obtain public input into the

selection of chemicals for evaluation,

the National Toxicology Program (NTP)

routinely announces in the Federal

Register the lists of chemicals for which

plans to develop protocols for

toxicological studies are underway. This

announcement will allow interested

parties to comment and provide

information on chemicals under

consideration. Chemicals and types of

studies under consideration are listed

below.

Allyl Bromide (CAS No. 106–95–6) is

used in both organic and biochemical

synthesis, commonly as a chemical

intermediate, in the synthesis of

perfumes and pharmaceuticals,

polymers and resins, and the production

of agricultural chemicals.

The National Cancer Institute

nominated allyl bromide based on

widespread use, its persistence as an

environmental pollutant and the lack of

toxicology data. There is potential for

human exposure both from production

and manufacturer as well as during its

end use. Possible routes of human

exposure include inhalation, oral and

dermal routes. Allyl bromide is one of

a group of organohalogen compounds

identified in waste water or drinking

water. Plans are underway to develop

protocols for toxicity and

carcinogenicity studies.

Divinylbenzene (CAS No. 1321–74–0)

(DVB) is a specialty monomer used in

polymer applications that require

additional heat resistance and strength.

It is used in styrene-butadiene rubber to

improve the swelling shrinkage, and

extrusion properties of the product. In

addition, DVB is used as a cross-linking

monomer for copolymerization with

styrene, and acrylic or methacrylic acid

to produce ion exchange resins.